Compazine Should Not Be Used for Schizophrenia Treatment in Pregnancy
Compazine (prochlorperazine) is not recommended for treating schizophrenia during pregnancy and should only be considered for severe, intractable nausea and vomiting when potential benefits outweigh risks. 1
Why Compazine Is Not Appropriate for Schizophrenia in Pregnancy
FDA Labeling Restrictions
The FDA drug label explicitly states that prochlorperazine is not recommended for use in pregnant patients except in cases of severe nausea and vomiting that are so serious and intractable that drug intervention is required and potential benefits outweigh possible hazards. 1 This narrow indication excludes its use for schizophrenia treatment during pregnancy.
Neonatal Risks
Prochlorperazine exposure during pregnancy carries significant risks to the neonate: 1
- Extrapyramidal signs (movement disorders)
- Prolonged jaundice
- Hyperreflexia or hyporeflexia
- Third-trimester exposure specifically increases risk for extrapyramidal and/or withdrawal symptoms after delivery, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorders 1
- Some neonates have required intensive care unit support and prolonged hospitalization 1
Recommended Approach for Schizophrenia Treatment in Pregnancy
First-Line Strategy
Continue antipsychotic treatment during pregnancy using evidence-based agents, as untreated schizophrenia poses greater risks to both mother and fetus than medication exposure. 2, 3 The risk of illness relapse with medication discontinuation is substantial and can interfere with prenatal care and infant care. 4, 2
Preferred Antipsychotic Selection
High-potency first-generation antipsychotics appear preferable for first-line management in pregnancy based on accumulated safety data. 5 While research shows that most antipsychotic medications used to treat schizophrenia appear relatively safe during pregnancy, no definitive association has been found between antipsychotic use during pregnancy and increased risk of birth defects. 4
Evidence on Antipsychotic Safety
One large Swedish registry study (2,908 women) found a modest increased risk for congenital malformations (OR 1.52,95% CI 1.05-2.19), primarily cardiovascular defects, but little drug specificity was noted, suggesting underlying pathology or confounding may explain the excess risk. 6 This study included women using prochlorperazine primarily for nausea, not schizophrenia treatment. 6
Treatment Principles During Pregnancy
- Use the minimum effective dose of an appropriate antipsychotic 5
- Continuous medication is needed given the high risk of decompensation during pregnancy and postpartum 5
- Shared decision-making with the patient about risks and benefits is essential 7, 8
- Monitor closely for maternal psychiatric stability and fetal well-being 3
Critical Pitfall to Avoid
Do not use prochlorperazine as a primary treatment for schizophrenia in pregnancy. It lacks FDA approval for this indication, has limited efficacy data for psychotic symptoms, and carries neonatal risks without the benefit of adequate maternal psychiatric stabilization. Instead, select from established antipsychotics with better evidence for treating schizophrenia during pregnancy. 4, 2, 3, 5